As of November 6, 2026, Taysha Gene Therapies, Inc. is a publicly traded company (Nasdaq: TSHA); its largest reported holder is RA Capital, with 9.9% on Schedule 13G/A of August 14, 2026, then RTW Investments (7%). The largest insider holding is Sean P. Nolan, the chief executive and a director, with 4,443,802 shares (1.4% of shares outstanding), per Form 4 of January 27, 2026 (Schedule 13G/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in Taysha Gene Therapies, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Taysha Gene Therapies, Inc. a real, registered company?
- Taysha Gene Therapies, Inc. files with the SEC under CIK 1806310 (its SEC filings).
- Its shares are listed under the ticker TSHA on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Dallas, Texas, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Taysha Gene Therapies, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names RA Capital (filed 2026-08-14).
Who are Taysha Gene Therapies, Inc.'s owners and officers?
Taysha Gene Therapies, Inc.: incorporated in Delaware; business address in Dallas, Texas; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-08-14).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2023-08-25)
- : Executive Officer (Form D, 2023-08-25)
- : Executive Officer, Director (Form D, 2023-08-25)
- : Director (Form D, 2023-08-25)
- : Director (Form D, 2023-08-25)
- : Director (Form D, 2023-08-25)
- : Director (Form D, 2023-08-25)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Ra Capital Management, L.P. | 9.9% |
| Schedule 13G/A, 2026-08-13 | Morgan Stanley | 5.1% |
| Schedule 13G/A, 2026-05-15 | Rtw Investments, LP | 7% |
| Schedule 13G/A, 2026-05-15 | Vestal Point Capital, LP | 6.3% |
| Schedule 13G/A, 2026-02-17 | Rtw Investments, LP | 8.3% |
| Schedule 13G, 2026-02-17 | Vestal Point Capital, LP | 5% |
| Schedule 13G/A, 2026-02-05 | Fmr LLC | 4.9% |
| Schedule 13G/A, 2026-01-21 | Blackrock, Inc. | 6.5% |
| Schedule 13G/A, 2025-11-14 | Octagon Capital Advisors LP | 3.3% |
| Schedule 13G/A, 2025-11-14 | Ra Capital Management, L.P. | 9.9% |
| Schedule 13G/A, 2025-08-14 | Ra Capital Management, L.P. | 9.9% |
| Schedule 13G/A, 2025-08-14 | Rtw Investments, LP | 9.9% |
Questions about who owns Taysha Gene Therapies, Inc.
Who owns Taysha Gene Therapies, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Taysha Gene Therapies, Inc.: Ra Capital Management, L.P. (9.9%, Schedule 13G/A, filed 2026-08-14), Rtw Investments, LP (7%, Schedule 13G/A, filed 2026-05-15), Blackrock, Inc. (6.5%, Schedule 13G/A, filed 2026-01-21), Vestal Point Capital, LP (6.3%, Schedule 13G/A, filed 2026-05-15) and Morgan Stanley (5.1%, Schedule 13G/A, filed 2026-08-13).
Who are the largest shareholders of Taysha Gene Therapies, Inc.?
By the share each holder's latest filing reports, the largest holders of Taysha Gene Therapies, Inc. on this page are Ra Capital Management, L.P. (9.9%), Rtw Investments, LP (7%) and Blackrock, Inc. (6.5%).
When did Ra Capital Management, L.P. buy into Taysha Gene Therapies, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Ra Capital Management, L.P. on this page is the Schedule 13G/A, filed 2025-08-14, reporting 9.9%; its latest, Schedule 13G/A filed 2026-08-14, reports 9.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Taysha Gene Therapies, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Taysha Gene Therapies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Taysha Gene Therapies, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Taysha Gene Therapies, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 4,443,802 shares (1.4% of shares outstanding), 2,908,257 held directly and 1,535,545 indirectly (Form 4, 2026-01-27).
- , a 10% owner: 2,841,704 shares (0.87% of shares outstanding), held indirectly (the form names the holder only in its footnotes) (Form 4, 2025-06-03).
- , a director: 2,060,849 shares (0.63% of shares outstanding), 1,176,559 held directly and 884,290 indirectly (Form 4, 2026-06-02).
- , the chief financial officer: 1,442,131 shares (0.44% of shares outstanding) (Form 4, 2026-02-06).
- , the president and head of r: 936,410 shares (0.29% of shares outstanding) (Form 4, 2026-07-10).
Shares outstanding: 325,833,545 as of 2026-08-11, from the company's latest SEC cover page.
How much has Taysha Gene Therapies, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2023-08-25 | $149.95M | $150M |
| Form D, 2022-11-07 | $30M | $30M |
Keep reading
More on Taysha Gene Therapies, Inc. and the records around it.
Taysha Gene Therapies, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Octagon Capital Advisors LP also filed stake reports on 8 other companies: Precision BioSciences, Inc. (Nov 2026), Context Therapeutics Inc. (Jul 2026), Corbus Pharmaceuticals Holdings, Inc. (May 2026)
- Vestal Point Capital, LP also filed stake reports on 27 other companies: Alto Neuroscience, Inc. (Aug 2026), iBio, Inc. (Aug 2026), Immunocore Holdings plc (Aug 2026)
- RTW Investments, LP also filed stake reports on 43 other companies: CG Oncology, Inc. (Aug 2026), iRhythm Holdings, Inc. (Aug 2026), Kailera Therapeutics, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/taysha-gene-therapies